NBSE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes...

Stats
Dzisiejszy wolumen	54 912.00
Średni wolumen	252 677
Kapitalizacja rynkowa	1.46M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.00700 (1.79%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-31	Symetryx Corp	Buy	0
2023-09-14	Symetryx Corp	Sell	129 108	Common Stock, Par Value $0.0001 per Share
2023-09-15	Symetryx Corp	Sell	103 337	Common Stock, Par Value $0.0001 per Share
2023-09-18	Symetryx Corp	Sell	50 000	Common Stock, Par Value $0.0001 per Share
2023-08-23	Symetryx Corp	Sell	0	Common Stock, Par Value $0.0001 per Share

INSIDER POWER
-20.25
Last 87 transactions
Buy: 13 371 397 \| Sell: 4 577 643

Wolumen Korelacja

Długi: -0.13 (neutral)

Krótki: 0.60 (weak)

Signal:(48.011) Neutral

NeuBase Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
LIAN	0.874
ATER	0.869
BPOPN	0.843
BIMI	0.829
LEGH	0.825
CDMOP	0.809
EQIX	0.808

10 Najbardziej negatywne korelacje
VMCAU	-0.856
OSN	-0.855
HSON	-0.827
LWAY	-0.822
ALR	-0.82
VFF	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NeuBase Therapeutics Inc Korelacja - Waluta/Towar

-0.40
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.15
( neutral )

NeuBase Therapeutics Inc Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$-1.26M (0.00 %)
EPS:	$-21.08

FY	2022
Przychody:	$0
Zysk brutto:	$-1.26M (0.00 %)
EPS:	$-21.08

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.930

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.890

Financial Reports:

No articles found.

NeuBase Therapeutics Inc

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Aktualne aktualizacje dla NeuBase Therapeutics Inc [NBSE]

Upcoming Earnings Alert